Drug
Bapineuzumab clinical trials
Also written AAB-001.
- studies test it
- 13
- open now
- 0
- in phase 3
- 7
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Pfizer (6) · JANSSEN Alzheimer Immunotherapy Research & Development, LLC (5) · Wyeth is now a wholly owned subsidiary of Pfizer (1) · Pharmacology Research Institute (1)
Studies
Open first, then newest update. How each study uses bapineuzumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous BapineuzumabTerminatedPhase 2PfizerNCT00916617Written as bapineuzumab
- Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsTerminatedPhase 3PfizerNCT00676143Written as bapineuzumab
- Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsTerminatedPhase 3PfizerNCT00667810Written as bapineuzumab
- A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsTerminatedPhase 3PfizerNCT00998764Written as Bapineuzumab 0.5 mg/kg
- Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers DiseaseCompletedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00397891Written as bapineuzumab
- A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease PatientsTerminatedPhase 3PfizerNCT00996918Written as Bapineuzumab 0.5 mg/kg
- A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 3JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT00937352Written as Bapineuzumab
- Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)CompletedPhase 3JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT00575055Written as Bapineuzumab 0.5 mg/kg
- Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)CompletedPhase 3JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT00574132Written as Bapineuzumab 0.5 mg/kg
- AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT00606476Written as Bapineuzumab (AAB-001)
- Study Evaluating Bapineuzumab In Alzheimer Disease SubjectsCompletedPhase 2PfizerNCT00663026Written as bapineuzumab
- Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownPhase 2Pharmacology Research InstituteNCT00174525Written as AAB-001
- AAB-001 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT00112073Written as bapineuzumab
Codes
What other systems call bapineuzumab · ClinicalTrials.gg INT005532
- MeSH (NLM) C545458bapineuzumabOne source NLM
- UNII (FDA) NC11WKO35DBAPINEUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3634466bapineuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79569BapineuzumabOne source FDA
- DrugBank DB11715One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545458 | bapineuzumab | One source NLM |
| UNII (FDA) | NC11WKO35D | BAPINEUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3634466 | bapineuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79569 | Bapineuzumab | One source FDA |
| DrugBank | DB11715 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.